This differential growth inhibition exhibited by the colon cancer cells to OX in the context of their p53 status implied that, HCT 116 cells bearing wild-type p53 was sensitive to OX treatment while HT 29 cells with mutant p53 were resistant or less sensitive to OX treatment. Here, TP53 is linked to colonic neoplasm.